Biogen Sues Over Sale of Alleged Copycat Alzheimer’s Antibody

Biogen Inc. sued Creative Biolabs Inc. in Boston federal court Wednesday for allegedly selling illegal copies of its aducanumab antibody, which is being investigated to treat early Alzheimer’s disease.

CB’s version of Biogen’s patented antibody would hurt both Biogen and the investigators who use the copycat product in research, the complaint says.

Biogen specializes in treating neurological diseases. It licensed aducanumab from Swiss biopharmaceutical company Neurimmune Therapeutics AG to collaborate on developing the antibody to treat Alzheimer’s. Biogen licenses a U.S. Patent covering the treatment from the University of Zurich.

“Although Defendant touts itself as a biotechnology company ‘developing novel ...